Ab­b­Vie’s trou­bled $10B Ro­va-T can­cer drug pro­gram takes a sud­den turn to­ward the cliff

The Ro­va-T prob­lem at Ab­b­Vie may be head­ed to­ward a full-fledged dis­as­ter.

Re­searchers slammed the brakes on one of their Phase III stud­ies of the $10 bil­lion drug af­ter an in­de­pen­dent group of mon­i­tors de­ter­mined that their drug was linked to a short­er over­all sur­vival rate than the chemo drug used in the con­trol arm.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER